September 19, 2014—Manufacturing disruptions are one of the most cited reasons for generic sterile injectable drug shortages, the journal Health Affairs reports in a new policy brief. Common problems include the inability to obtain raw materials from foreign sources, discovering quality issues such as foreign particulate in the product, or prolonged efforts to upgrade and modernize factories.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)